LONG-TERM OUTCOMES WITH EMICIZUMAB PROPHYLAXIS FOR SEVERE HAEMOPHILIA A WITHOUT FVIII INHIBITORS: EFFICACY AND SAFETY ANALYSES FROM HAVEN 3 & 4

被引：0
|
作者：
Mahlangu, J. [1 ,2 ]
Jimenez-Yuste, V. [3 ]
Ventriglia, G. [4 ]
Niggli, M. [4 ]
Barlera, S. [5 ]
Hermans, C. [6 ]
Lehle, M. [4 ]
Chowdary, P. [7 ]
Jew, L. [8 ]
Windyga, J. [9 ]
Frenzel, L. [10 ]
Castaman, G. [11 ]
Pipe, S. W. [12 ]
机构：
[1] Univ Witwatersrand, Johannesburg, South Africa
[2] NHLS, Johannesburg, South Africa
[3] Univ Autonoma Madrid, La Paz Univ Hosp, Madrid, Spain
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Parexel Int, Milan, Italy
[6] Catholic Univ Louvain UCLouvain, Univ Clin St Luke, Brussels, Belgium
[7] Royal Free London, Katharine Dormandy Haemophilia & Thrombosis Unit, London, England
[8] Genentech Inc, San Francisco, CA USA
[9] Inst Hematol & Transfus Med, Dept Hemostasis Disorders & Internal Med, Lab Hemostasis andMetabol Dis, Warsaw, Poland
[10] Necker Enfants Malades Hosp, Dept Hematol, Paris, France
[11] Careggi Univ Hosp, Florence, Italy
[12] Univ Michigan, Dept Pediat & Pathol, Ann Arbor, MI USA
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO135
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [31] Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
    Shapiro, Amy D.
    Angchaisuksiri, Pantep
    Astermark, Jan
    Benson, Gary
    Castaman, Giancarlo
    Eichler, Hermann
    Jimenez-Yuste, Victor
    Kavakli, Kaan
    Matsushita, Tadashi
    Poulsen, Lone Hvitfeldt
    Wheeler, Allison P.
    Young, Guy
    Zupancic-Salek, Silva
    Oldenburg, Johannes
    Chowdary, Pratima
    BLOOD ADVANCES, 2022, 6 (11) : 3422 - 3432
  • [32] Long-term safety and efficacy of emicizumab for up to 5.8 years and patients' perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A
    Shima, Midori
    Nagao, Azusa
    Taki, Masashi
    Matsushita, Tadashi
    Oshida, Koichi
    Amano, Kagehiro
    Nagami, Sayaka
    Okada, Norihiro
    Maisawa, Shingo
    Nogami, Keiji
    HAEMOPHILIA, 2021, 27 (01) : 81 - 89
  • [33] Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial
    Reyes, Adriana
    Revir, Cedric
    Niggli, Markus
    Chebon, Sammy
    Schlagmueller, Simone
    Flacke, Jan-Paul
    Zortel, Max
    Paz-Priel, Ido
    Asikanius, Elina
    Hampton, Roger
    Mahajan, Anadi
    Schmidt, Elvira
    Edwards, Susan C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (12) : 2079 - 2087
  • [34] Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands
    van Dijk, K
    Fischer, K
    van der Bom, JG
    Scheibel, E
    Ingerslev, J
    van den Berg, HM
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (01) : 107 - 112
  • [35] A long term outcomes analysis of severe haemophilia A boys receiving 4 years prophylaxis on the Chinese Haemophilia Individualized escalating low dose Prophylaxis (CHIPS)
    Yao, Wanru
    Ai, Di
    Zhang, Qing
    Li, Xiaojing
    Zhou, Min
    Zhang, Ningning
    Yang, Sheng
    Chen, Zhenping
    Zhen, Yingzi
    Luke, Koon-Hung
    Wu, Runhui
    THROMBOSIS RESEARCH, 2024, 241
  • [36] LONGER-TERM EFFICACY AND SAFETY OF CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: RESULTS FROM THE EXTENSION PART OF THE PHASE 2 EXPLORER5 TRIAL
    Eichler, H.
    Angchaisuksiri, P.
    Astermark, J.
    Benson, G.
    Cepo, K.
    Chowdary, P.
    Hansen, T.
    Kavakli, K.
    Wheeler, A. P.
    Oldenburg, J.
    HAEMOPHILIA, 2021, 27 : 95 - 95
  • [37] LONG-TERM OUTCOMES OF PREVIOUSLY-TREATED ADULT AND ADOLESCENT PATIENTS WITH SEVERE HAEMOPHILIA A RECEIVING PROPHYLAXIS WITH EXTENDED HALF-LIFE FVIII TREATMENTS: AN ECONOMIC ANALYSIS FROM A UK PERSPECTIVE
    Benson, G.
    Morton, T.
    Thomas, H.
    Lee, X. Y.
    VALUE IN HEALTH, 2020, 23 : S696 - S696
  • [38] EMICIZUMAB PROPHYLAXIS IMPROVES ACUTE AND CHRONIC PAIN-RELATED OUTCOMES IN PEOPLE WITH HAEMOPHILIA A (PWHA): POST HOC ANALYSIS OF 470 PATIENTS FROM HAVEN 1, 3, 4 AND STASEY
    Hermans, C.
    Skinner, M. W.
    Gentile, B.
    Lim, E.
    Minhas, M.
    Moreno, K.
    Tzeng, E.
    Buckner, T. W.
    HAEMOPHILIA, 2023, 29 : 79 - 80
  • [39] EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A (PWHA), AGED ≥50 YEARS, WITH COMORBIDITIES - POOLED DATA FROM FOUR PHASE 3 STUDIES (HAVEN 1, 3, 4, AND STASEY)
    Jimenez-Yuste, V.
    Oldenburg, J.
    Tzeng, E.
    Trzaskoma, B.
    Sanabria, F.
    Mahlangu, J.
    HAEMOPHILIA, 2022, 28 : 50 - 50
  • [40] Long-Term Immunogenicity, Safety and Efficacy of Human-cl rhFVIII in Previously Treated Children with Severe Haemophilia A
    Klukowska, A.
    Vdovin, V.
    Szczepanski, T.
    Bichler, J.
    Dzhunova, I.
    Liesner, R.
    HAEMOPHILIA, 2016, 22 : 96 - 96
12345